Asana BioSciences to present clinical data on oral ASN007, a novel ERK1/2 inhibitor, at the 32nd EORTC-NCI-AACR Symposium
LAWRENCEVILLE, N.J.–(BUSINESS WIRE)–Asana BioSciences, a clinical stage biopharmaceutical company, announced that ASN007 clinical data on safety, efficacy and pharmacokinetics in solid tumor patients will be presented at the 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020) to be
